Luteolin — Supplements
Flavonoid senolytic with 2024 Nature Aging evidence — disrupts p16-CDK6 interaction and exhibits stronger senolytic activity than quercetin in head-to-head 2024 comparisons.
Overview
Luteolin (3',4',5,7-tetrahydroxyflavone) is a polyphenolic flavonoid found abundantly in celery, parsley, thyme, chamomile, and artichoke. It has emerged as a significant senolytic and senomorphic compound based on a convergence of 2024 publications. A July 2024 Nature Aging study demonstrated that a luteolin-standardized extract of Salvia haenkei extended both lifespan and healthspan in naturally aged mice, reducing inflammation, fibrosis, and senescence markers across multiple tissues via disruption of the p16–CDK6 protein-protein interaction. A separate October 2024 BioRxiv study conducting direct head-to-head comparisons found luteolin exhibits stronger senolytic activity than quercetin in eliminating senescent cells. In neurological models, luteolin attenuated D-galactose-induced brain aging in rats via senolytic, anti-inflammatory, and anti-apoptotic mechanisms, upregulating SIRT1 and downregulating the AGEs/RAGE/p21 pathway. Luteolin also demonstrates SASP suppression — reducing IL-6, TNF-α, and MMP secretion from senescent cells — making it both senolytic and senomorphic. Unlike dasatinib and navitoclax, which target BCL-2 family proteins directly, luteolin's primary senolytic mechanism operates through the CDK inhibitor pathway (p16–CDK6), representing a mechanistically distinct and complementary approach.
Indications
- Biological aging and senescent cell clearance (investigational)
- Neuroinflammation and brain aging
- SASP-driven chronic inflammation
- Osteoarthritis and joint senescence (animal model evidence)
- Immune senescence and inflammaging
Mechanism of Action
Luteolin directly disrupts the p16INK4a–CDK6 protein-protein interaction — a key axis sustaining the senescent phenotype. By blocking this interaction, luteolin re-enables CDK6 activity, allowing senescent cells to undergo apoptosis rather than permanent growth arrest
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Luteolin (free aglycone) | 100–400 mg | Once daily with food | Fat-containing meal improves absorption of this lipophilic flavonoid; typical supplement doses; senolytic dose in humans not yet validated |
| Luteolin (as Salvia haenkei standardized extract) | Per label standardization | Once daily | Branded extract form used in 2024 Nature Aging research; consult product COA for luteolin content |
Evidence Grade
GRADE C
Safety & Contraindications
- Generally well tolerated in animal studies at doses up to 200 mg/kg; no significant adverse effects reported
- No completed Phase 2 human senolytic trials as of 2025 — human senolytic efficacy data is limited to cell and animal models
- CYP1A2 and CYP2C8 inhibitor in vitro — potential drug interactions at high doses with substrates like warfarin, theophylline; clinical significance at supplement doses uncertain
- Thyroid peroxidase inhibition reported in vitro — use caution in thyroid disease or with levothyroxine (monitor TSH)
- Anti-platelet effects documented — avoid combining with anticoagulants without monitoring
- Avoid in pregnancy — insufficient safety data; luteolin has shown embryotoxic effects in some animal studies at high doses
- Most commercial products derived from chamomile or citrus peel — standardization to luteolin content varies widely